Investment Pitches

Pitch Summary:
Centene is one of the largest health insurers in the U.S. The company specializes in three major government-sponsored programs: Medicaid, Marketplace and Medicare Advantage, each of which benefits from long-term secular tailwinds. In Medicaid, states are steadily outsourcing their programs to companies like Centene to reduce costs and improve care quality. Managed Medicaid penetration has increased throughout the past decade and we expect further gains over time. In Marketplace, growth is driven by the trend toward more individuals buying health insurance. Centene holds the #1 market share in both of these programs and is well positioned to capitalize on their continued growth. Finally, we believe management is successfully turning around Centene's Medicare business and expect the division to generate positive earnings over time. After adjusting for losses stemming from Centene's Medicare business, we were able to purchase shares at a single-digit P/E multiple, which we think is too cheap for a leading, secularly growing Medicaid company and an improving Medicare business.

BSD Analysis:
Oakmark presents a compelling value thesis for Centene, emphasizing the company's dominant market position in government-sponsored healthcare programs. The managers highlight three key growth drivers: expanding Medicaid outsourcing by states, increasing individual health insurance adoption in Marketplace plans, and a turnaround in Medicare operations. Centene's #1 market share in both Medicaid and Marketplace positions provides significant competitive advantages and exposure to secular healthcare trends. The fund's ability to purchase shares at a single-digit P/E multiple after adjusting for Medicare losses suggests attractive entry valuation. The thesis relies on management's execution of the Medicare turnaround and continued penetration gains in managed Medicaid. This represents a classic value play on a market leader trading at distressed multiples due to temporary operational challenges.

Pitch Summary:
We previously divested from Meta during a period of stagnant advertising growth and the company's initial, significant investment in the metaverse project. At that time, investors appeared complacent to the risks associated to an increasingly competitive landscape, and the Street's robust financial expectations as the company transitioned towards monetizing short-format video (Reels). The subsequent decline in Meta's stock price during 2022 reflected these concerns. Since then, Meta has demonstrably shifted its strategic focus. The company has prioritized operational efficiency, implemented strategies to monetize Reels effectively, and initiated a robust artificial intelligence (AI) development program. We believe the focus on AI represents a more prudent capital allocation strategy compared to the earlier metaverse initiative. Meta AI holds significant potential to unlock substantial monetization opportunities and enhance user engagement, while maintaining tight controls on operating costs. Meta's unparalleled global reach, fostered by its extensive suite of applications, translates to a dominant position within digital advertising. This competitive advantage is further bolstered by the difficulty of replicating Meta's user base. We anticipate that the company's ability to expand its global advertising market share and leverage AI for innovative business ventures should translate into 13-15% intrinsic value growth per annum. Undoubtedly, Meta faces ongoing challenges regarding user data privacy and content control. While regulatory scrutiny is likely to persist, we believe the long-term impact on intrinsic value should be minimal. Although increased legal costs are a consequence, greater data and content supervision could strengthen Meta's competitive moat.

BSD Analysis:
Mar Vista re-initiated a position in Meta after previously divesting during the company's challenging metaverse investment period and stagnant advertising growth. The fund believes Meta has successfully shifted strategic focus toward operational efficiency, effective Reels monetization, and robust AI development, representing more prudent capital allocation than the earlier metaverse initiative. The manager highlights Meta's unparalleled global reach through its application suite, creating a dominant digital advertising position that's difficult to replicate. Meta AI is viewed as having significant potential to unlock monetization opportunities and enhance user engagement while maintaining cost discipline. The fund projects 13-15% annual intrinsic value growth driven by expanding global advertising market share and AI-leveraged business ventures. While acknowledging ongoing challenges around data privacy and content control, Mar Vista believes regulatory scrutiny will have minimal long-term impact on intrinsic value. The manager suggests that increased data and content supervision could actually strengthen Meta's competitive moat. This bullish thesis reflects confidence in Meta's strategic pivot toward AI and operational efficiency after learning from the metaverse investment experience.

Pitch Summary:
Linde PLC is the world's largest, global industrial gas producer. The company enjoys the highest profit margins and returns on capital in the industry. Linde's primary products are atmospheric gases and process gases. Industrial gases have benefitted from secular growth trends in decarbonization and carbon sequestration. Moreover, the opportunity in blue and green ammonia and hydrogen are substantial. Projects in these areas are quickly being added to its backlog for future growth. We see these secular trends as long-term positives for Linde and the entire industrial gas industry. Linde believes it can grow its volumes with new applications; the buildout of small, on-site plants using its technologies; and focusing on growing geographies such as India, Malaysia, Vietnam, China and Brazil. Despite the long-term growth opportunities, recent demand trends have slowed due to weak global industrial production. Among the regions, the U.S. remains resilient, with volumes flat to slightly negative. Europe, Latin America, the Middle East, and China are all sending mixed economic signals. We believe these slower trends are transitory in nature, providing an opportunity to purchase shares in Linde at attractive prices.

BSD Analysis:
Mar Vista views Linde as the world's largest industrial gas producer with industry-leading profit margins and returns on capital, making it an attractive long-term investment. The fund highlights Linde's exposure to secular growth trends in decarbonization and carbon sequestration, with substantial opportunities in blue and green ammonia and hydrogen projects being added to the backlog. The manager believes Linde can drive volume growth through new applications, on-site plant buildouts, and expansion in high-growth geographies including India, Malaysia, Vietnam, China, and Brazil. While acknowledging near-term headwinds from weak global industrial production and mixed regional economic signals, Mar Vista views these challenges as transitory. The fund sees the current environment as providing an opportunity to purchase shares at attractive prices given the long-term secular tailwinds. Mar Vista's bullish stance reflects confidence in Linde's market leadership position and its ability to capitalize on the global transition toward cleaner energy and industrial processes. The investment thesis centers on Linde's superior competitive position and exposure to multi-decade decarbonization trends.

Pitch Summary:
We initiated a position in Broadcom in Q2. As a skilled aggregator, Broadcom acquires firms, streamlines their operations, and invests R&D dollars in mission critical products that generate industry leading profit margins, robust cash flows and high returns on invested capital. Its primary markets include AI accelerators targeting generative AI applications, networking & wireless semiconductors, and mission-critical infrastructure software solutions. Broadcom is well-positioned to benefit from the rapidly expanding demand for custom AI accelerator chips that support the evolution of the generative AI market. The company is the second-largest producer of AI accelerator chips behind Nvidia and leads the market in custom AI ASIC chips. Its customers include leading hyper scalers like Alphabet and Meta who are turning to Broadcom for custom silicon due to its performance and cost advantages. We believe the company is a direct beneficiary of a multi-year capital cycle driven by hyper scalers building out next-generation AI factories. Broadcom recently acquired VMware, the leader in virtualization software targeting the enterprise market. The integration of VMware is tracking ahead of plan as management has simplified its product bundles, transitioned to a subscription revenue model, and reduced operating costs. We believe this simplified go-to-market structure will result in strong top-line revenue growth and expanding operating margins. We believe Broadcom will compound intrinsic value per share in the mid-20% range over the intermediate term as it benefits from the AI-infrastructure build-out, a cyclical recovery in its legacy semiconductor business, and modestly accelerating growth from its infrastructure software business as VMware is successfully integrated.

BSD Analysis:
Mar Vista initiated a new position in Broadcom, viewing the company as a skilled aggregator with a proven track record of acquiring companies and optimizing operations for superior returns. The fund highlights Broadcom's position as the second-largest producer of AI accelerator chips behind Nvidia, with particular strength in custom AI ASIC chips for hyperscalers like Alphabet and Meta. The manager believes Broadcom is a direct beneficiary of the multi-year AI infrastructure buildout, with customers choosing Broadcom for performance and cost advantages in custom silicon. The recent VMware acquisition is progressing ahead of schedule, with management successfully simplifying product bundles, transitioning to subscription revenue, and reducing costs. Mar Vista expects this integration to drive strong revenue growth and margin expansion through improved go-to-market efficiency. The fund projects mid-20% intrinsic value growth over the intermediate term, driven by AI infrastructure demand, cyclical recovery in legacy semiconductors, and accelerating software growth from VMware integration. This bullish thesis positions Broadcom as a key beneficiary of the AI revolution across both hardware and software segments.

Pitch Summary:
Oracle is seeing revenue acceleration as it benefits from several years of investing in cloud-based solutions that are now driving demand. Oracle's OCI offering is recognized as a viable hyper scaler offering and is winning mindshare from leading cloud customers including Open AI. This is driving accelerating demand as it offers a strong value proposition to customers due to its favorable performance and cost metrics. This coupled with Oracle's recently announced partnerships with Microsoft Azure and Google Compute Platform, which could help facilitate the migration of the Oracle Database to the cloud. We believe this should support a third leg of growth for Oracle as its large installed base of database customers shift from on-premise to cloud deployments. As database customers migrate to the cloud, Oracle could increase database software support revenues by two-to-three times. We continue to believe Oracle is well positioned to grow intrinsic value low-double-digits over our investment horizon.

BSD Analysis:
Mar Vista maintains a bullish view on Oracle, highlighting the company's successful transition to cloud-based solutions after years of strategic investment. The fund emphasizes Oracle's OCI platform as a credible hyperscaler offering that's gaining traction with major customers like OpenAI due to superior performance and cost metrics. Strategic partnerships with Microsoft Azure and Google Cloud Platform are expected to accelerate Oracle Database migration to the cloud, creating a significant growth catalyst. The manager identifies this cloud migration as a "third leg of growth" for Oracle, leveraging its substantial installed base of database customers. Mar Vista projects that cloud migration could increase database software support revenues by two to three times, representing substantial revenue expansion potential. The fund expects Oracle to deliver low-double-digit intrinsic value growth over their investment horizon. This bullish thesis centers on Oracle's competitive positioning in cloud infrastructure and the monetization opportunity from migrating existing customers to higher-value cloud deployments.

Pitch Summary:
Alphabet reported robust quarterly financials, demonstrating accelerated revenue growth and improved margins from restructuring efforts. The company's core advertising business is rebounding after a challenging 2022-2023 period, when advertisers curtailed spending due to economic concerns. While this quarter's exceptional growth rate may not persist, Alphabet's performance indicates it is likely to exceed our annual projections. Following Meta's lead, Alphabet is adopting a more stringent approach to expenses. The company continues to reduce headcount and consolidate teams, aiming to counterbalance the impact of infrastructure investments on profitability. Alphabet's better-than-expected revenue and earnings underscore both the resilience of its core business and management's early success in sustainably restructuring the cost base. Notably, AI advancements are already showing promising results, enhancing consumer engagement, and improving advertiser performance. These developments position Alphabet favorably in an increasingly AI-driven digital landscape.

BSD Analysis:
Mar Vista is bullish on Alphabet following strong quarterly results that demonstrated accelerated revenue growth and margin expansion from successful restructuring efforts. The fund notes that Alphabet's core advertising business has rebounded strongly after a challenging 2022-2023 period when economic concerns pressured advertiser spending. Management's disciplined approach to cost control, including headcount reductions and team consolidation, is helping offset infrastructure investment costs while maintaining profitability. The manager believes Alphabet's performance indicates the company will likely exceed annual projections. AI advancements are already delivering tangible benefits through enhanced consumer engagement and improved advertiser performance. The fund views these AI developments as positioning Alphabet favorably in an increasingly AI-driven digital advertising landscape. Mar Vista's positive stance reflects confidence in both the resilience of Alphabet's core business model and management's execution of operational improvements.

Pitch Summary:
Investors were reminded of the strength of the Apple ecosystem as management demonstrated how generative AI solutions would be integrated into Apple's 1.2 billion iPhone installed base. Apple plans to integrate generative AI features into its iOS 18, which will be broadly released in the fall with the iPhone 16. We believe Apple should benefit from generative AI as it will spur a meaningful iPhone upgrade cycle and create new avenues of monetization through its app store and advertising offerings. We believe this will support intrinsic value growth that will range between high-single-digits and low-double-digits over our investment horizon.

BSD Analysis:
Mar Vista views Apple as a direct beneficiary of the generative AI revolution, with the company's massive 1.2 billion iPhone installed base providing a significant competitive advantage. The fund believes Apple's integration of AI features into iOS 18 will drive a meaningful upgrade cycle, creating substantial revenue opportunities. The manager highlights Apple's ecosystem strength and expects new monetization avenues through the App Store and advertising. With generative AI capabilities set to launch with the iPhone 16, Apple is positioned to capitalize on consumer demand for AI-enabled devices. The fund projects intrinsic value growth in the high-single-digit to low-double-digit range, reflecting confidence in Apple's ability to monetize its AI investments. The thesis centers on Apple's unique position to leverage its existing user base for AI adoption. Mar Vista's bullish stance reflects their belief that Apple's AI integration will drive both hardware upgrades and services revenue growth.

Pitch Summary:
MEG Energy is a pure-play oil sands producer situated in Alberta's Athabasca region. The company's primary producing asset is located at Christina Lake, approximately 150 kilometers south of Fort McMurray. As a leading upstream operator, MEG employs steam-assisted gravity drainage (SAGD) technology at their Christina Lake project. This process injects steam into an oil reservoir to heat the bitumen found deep underground, reducing its viscosity and enabling the extraction of heavy crude by pumping it to the surface. The company monitors the efficiency of its SAGD operations using the steam-oil ratio (SOR), an industry-wide proxy used to assess the efficiency of thermal oil recovery. In 2023, MEG achieved an impressive SOR of 2.2, with a ratio below 3 considered very efficient. Only two companies hold the status of having the lowest SORs in the industry and MEG is one of them. The other company also operates projects at Christina Lake. As one of Canada's most prestigious oil-producing regions, MEG's Christina Lake project boasts approximately 2 billion barrels of proved and probable reserves, ensuring over 50 years of production life for the company. MEG began its journey in 1999 by acquiring nine sections in the then-obscure Christina Lake region of Northern Alberta by founder Bill McCaffrey. McCaffrey, an engineer who worked for Amoco Canada (bought by BP Oil in 1998) for over 17 years before MEG, founded the company with his brother-in-law, Steve Turner and friend, Dave Wizinsky. The three financed the purchase with savings, each contributing around $100,000. This investment allowed them to acquire the nine sections for $150,000, and thus, McCaffrey Energy Group (later renamed MEG) was born. At the time, oil prices were just $11 per barrel and the prevailing sentiment concerning the oil sands was skeptical. At the time, the market was dominated by well-capitalized players such as Syncrude, Suncor and Imperial Oil. However, McCaffrey recognized the potential of the region and took a long-term view on the region which contained roughly a billion barrels of oil in place at the time, costing them roughly 1.5 cents per barrel. For the first four years of operations, McCaffrey focused on acquiring high-quality oil sand leases, without prioritizing the development of an oil sands operation. With valuable assets and solid expertise, the next step was to secure funding. Between 2004 and 2009, the company attracted several blue-chip investors, including pension, endowment, sovereign wealth funds, and private equity, raising approximately $3.2 billion—one of the largest capital raises for a North American company in the pre-initial offering stage. McCaffrey delivered on his promises, and MEG's production steadily increased. In 2013, the company produced an average of 35,000 barrels per day, a 23% increase from the previous year. Within a decade, MEG's market capitalization soared to over $9 billion, and today is producing over 110,000 barrels of oil per day at Christina Lake, with regulatory approvals in place to produce approximately 210,000 barrels per day. In 2018, MEG received an unsolicited offer from Husky Energy (which was acquired by Cenovus in 2021) to buy the company for $11 per share, representing a 37% premium over MEG's then-share price of $8. At the time, MEG was undergoing a transition following the resignation of CEO Bill McCaffrey. The company focused on repaying its sizeable debt, expanding its marketing efforts, and boosting production. The newly appointed CEO, Derek Evans, who led MEG from 2018-2024, rejected Husky's offer, arguing that it significantly undervalued MEG's assets, technology, expertise, and business prospects. Husky eventually abandoned their 105-day pursuit in early 2019, causing MEG's share price to fall by over 35%. In the years following the attempted takeover, MEG significantly improved its balance sheet, reducing debt from over $3 billion in 2018 to $730 million by the end of 2023. In the second quarter of 2022, MEG initiated its first share buyback program and has committed to dedicate 100% of its free cash flow to shareholders exclusively through share repurchases once the company achieves its target debt of $600 million, which is expected to be very soon. Today, MEG is a markedly different company, benefiting from a sharp rise in oil prices due to supply constraints and geopolitical concerns. The world has turned its attention to Canadian oil sands, appreciating their long-life reserves and access to international markets, contributing to MEG's strengthened position. MEG has distinguished itself from the large integrated oil sand producers through a disciplined strategy to be a low-cost producer and exceptional operator. This is evidenced by the company's breakeven price per barrel of US$46, with production and transportation costs at approximately CAD$25 per barrel. These costs are also further offset by cogeneration as MEG uses a gas turbine as part of its production process that generates electrical power where the excess power generated is sold to Alberta's power grid. MEG's operational excellence is emphasized by its low average annual production decline rate of 10-15%, translating into very low sustaining capital requirements for the company. To help put this into perspective, the top six Permian supermajors in the US have a base decline rate of 32%, requiring them to replace the equivalent of one Canadian Natural Resources (approximately 1.4 million barrels of oil equivalent per day) every single year just to maintain flat production. This significant difference explains the recent consolidation in the US, where US producers are forced to acquire assets to maintain reserves as they historically prioritized unfettered growth over sensible capital allocation. In contrast, MEG focuses on sustaining its production over the long-term to generate free cash flow for shareholders without the need to acquire additional assets, due to its long-life reserves. MEG plans to grow production per share 10% in 2024, with 6% coming from share buybacks and a steady 4% from organic production growth. Instead of putting all their capital directly into the ground, management will take their time and prioritize sustainable growth over rapid expansion, which would quickly diminish their long-life reserves at Christina Lake, a wonderful example of prudent and efficient capital allocation. Looking ahead, we believe MEG will benefit significantly from the long-awaited Trans Mountain pipeline expansion, which took effect in early May. The new infrastructure will triple capacity, allowing producers in Canada like MEG to ship an additional 590,000 barrels per day to customers. MEG is poised to benefit by providing 20,000 barrels per day of contracted transportation capacity to Canada's West Coast through the pipeline. Additionally, MEG will also benefit via better pricing, as for years Canadian heavy oil has traded at a steep discount to lighter US crude, but has recently narrowed from 19% in 2022 and 2023 to 12% in May. At the time of writing, oil prices stand at over $80 WTI per barrel, making MEG a very profitable business that generates substantial free cash flow for shareholders without requiring vast amounts of capital to continue operations, due to their superb operational efficiencies and preservation of its long-life reserves. As mentioned in our first-quarter newsletter, we decided to double our position in MEG by selling our previous position in Suncor. We believe MEG is growing more quickly, trades at a lower valuation, and provides better exposure to oil prices, which we expect to continue rising as the world comprehends the essential requirement for oil and gas and looks to Canada as the appropriate resolution.

BSD Analysis:
ROCKLINC presents a compelling bull case for MEG Energy, emphasizing the company's operational excellence and strategic positioning in Canada's oil sands sector. The manager highlights MEG's industry-leading steam-oil ratio of 2.2, which demonstrates exceptional operational efficiency in extracting bitumen from oil sands deposits. The company's low breakeven price of US$46 per barrel and production costs of approximately CAD$25 per barrel provide significant margin of safety at current oil prices above $80 WTI. MEG's superior capital allocation strategy is evident in its low 10-15% annual production decline rate compared to 32% for major US Permian producers, requiring minimal sustaining capital expenditure. The firm's balance sheet transformation from over $3 billion debt in 2018 to $730 million by 2023, combined with its commitment to return 100% of free cash flow to shareholders through buybacks once reaching $600 million debt target, demonstrates disciplined financial management. The Trans Mountain pipeline expansion provides a significant catalyst, offering MEG contracted capacity of 20,000 barrels per day to West Coast markets and narrowing the discount between Canadian heavy oil and US crude from 19% to 12%. ROCKLINC doubled their position by selling Suncor, viewing MEG as offering superior growth, lower valuation, and better oil price exposure.

Pitch Summary:
Ryanair is Europe's largest airline by passenger volume (~20% market share). It employs a very simple, yet unique business model. It flies only point-to-point, books flights almost solely through its website/app, heavily utilizes secondary airports, flies a single-variant fleet, and has a widespread geographic distribution (40 countries and 96 bases), which helps mitigate the impact of strikes or unfavorable regulations that occur in a single geography. Ryanair is one of the only international airlines to post high growth and stellar returns through a full cycle, owing mostly to the company's obsessive focus around efficiency and agility. Ryanair has created a deep cost advantage that allows it to price fares at levels that would be unprofitable for the vast majority of peers, leading to continued market share gains. The current industry setup is favorable, as the European in-service short-haul fleet is in short supply. Elevated storage rates are unlikely to revert due to aircraft age and restoration costs. Additionally, there are supply chain challenges and large backlogs that are limiting the pace of delivery of new planes. Ryanair's mid-single-digit capacity growth is locked in through 2034. Recently, its fares have been a bit softer than expected due to a weak consumer in Europe, and capacity hasn't expanded as quickly as expected due to Boeing delivery delays. We view both issues as transitory in nature. Valuation is well below historical averages and is likely to recover over a 3-5 year time horizon.

BSD Analysis:
FMI presents a compelling bull case for Ryanair based on its dominant 20% market share in European passenger volume and unique low-cost business model. The manager emphasizes Ryanair's operational efficiency through point-to-point flights, direct booking, secondary airports, single-variant fleet, and geographic diversification across 40 countries and 96 bases. This model has enabled the company to achieve high growth and strong returns through full cycles while creating a sustainable cost advantage that allows unprofitably low pricing for competitors. Current industry dynamics are favorable with European short-haul fleet shortages, elevated storage costs, and supply chain constraints limiting new aircraft deliveries. Ryanair's capacity growth is secured through 2034, providing visibility into future expansion. Near-term headwinds from weak European consumer demand and Boeing delivery delays are viewed as temporary issues. The manager sees significant upside potential with valuation well below historical averages and expects recovery over a 3-5 year timeframe.

Pitch Summary:
Quest Diagnostics is one of the largest independent clinical laboratory testing companies in the U.S. with a 24% market share of independent lab testing, and its scale gives it a cost advantage. The clinical testing industry sees steady volume growth, helped by increasing test volume due to an aging population, higher prevalence of chronic disease, and advancements in medical technology that continue to expand the scope of clinical testing. The broader lab industry is an $85 billion market, accounting for only 2% of total healthcare spending, yet influencing over 70% of medical decisions. Today, nearly 60% of diagnostic tests are performed in a hospital or at a hospital outreach laboratory. Importantly, performing the same diagnostic test at an independent lab can cost anywhere between two and five times less than performing the same test in a hospital lab. Quest's average revenue per requisition is under $50. There is a nationwide focus on increasing preventative healthcare and lowering healthcare costs in general. Independent labs are part of the solution, as there is a huge value to be reaped by pushing more volumes through them. In the past, Quest has seen reimbursement challenges from both government and commercial payors. We believe that reimbursement headwinds have largely abated due to all payors recognizing the large cost-benefit of higher volumes flowing through the independent labs. We expect Quest to generate mid-single-digit topline growth and expand margins, leading to high-single-digit earnings growth. With Quest's dividend and share repurchases, there are prospects for a low-double-digit total annual return, which is attractive given the defensive nature of the business and well-below market valuation.

BSD Analysis:
FMI's bull thesis for Quest Diagnostics centers on the company's dominant 24% market share in independent lab testing and significant cost advantages from scale. The manager highlights compelling industry dynamics including steady volume growth driven by aging demographics, chronic disease prevalence, and expanding medical technology capabilities. A key value proposition is Quest's cost efficiency, with independent lab testing costing 2-5 times less than hospital-based testing while Quest's average revenue per requisition remains under $50. The investment case is strengthened by the $85 billion lab industry representing only 2% of healthcare spending yet influencing 70% of medical decisions, suggesting significant growth runway. FMI believes reimbursement headwinds have abated as payors recognize the cost-benefit of independent labs, positioning Quest for mid-single-digit revenue growth and margin expansion. The manager projects high-single-digit earnings growth with low-double-digit total returns through dividends and share repurchases, attractive given the defensive business model and below-market valuation.

Pitch Summary:
Henry Schein is the largest dental distributor in the world, holding a leading market share position in all of its main geographies, and is also a leader in medical distribution. Henry Schein provides value to both product manufacturers and its customers. Manufacturers benefit from cost effective access to a highly fragmented customer base, as well as sales and marketing support for products. Practitioner customers benefit from timely access to a broad range of products, a reduction in the number of vendors they need to deal with directly, inventory management services, and equipment servicing. Henry Schein also sells practice management software that is used by ~40% of dental practices in the U.S., which is a very sticky business. We expect continued strong long-term growth in spending on dental services, which will be driven by an aging population, along with a focus on preventive care and demand for cosmetic dentistry procedures. Schein's stock has been under pressure in the near term because it is still recovering from a cyber-attack that took place late last year, and the macro backdrop continues to be challenged, which has led to muted elective/discretionary sales across the business. The stock is trading well below the market, which we view as attractive given its above-average business quality.

BSD Analysis:
FMI presents a compelling bull case for Henry Schein based on its dominant market position as the world's largest dental distributor with leading market share across key geographies. The manager emphasizes the company's value proposition to both manufacturers and practitioners, highlighting cost-effective customer access and comprehensive service offerings including inventory management and equipment servicing. A key competitive advantage is Henry Schein's practice management software used by approximately 40% of U.S. dental practices, creating significant customer stickiness. The investment thesis centers on secular growth drivers including an aging population, increased focus on preventive care, and rising demand for cosmetic dentistry procedures. Near-term headwinds from a cyber-attack and challenging macro conditions have created an attractive entry point, with the stock trading below market multiples despite above-average business quality. The manager views current pressures as temporary while the long-term fundamentals remain intact.

Pitch Summary:
Ryanair is Europe's largest airline by passenger volume (~20% market share). It employs a very simple, yet unique business model. It flies only point-to-point, books flights almost solely through its website/app, heavily utilizes secondary airports, flies a single-variant fleet, and has a widespread geographic distribution (40 countries and 96 bases), which helps mitigate the impact of strikes or unfavorable regulations that occur in a single geography. Ryanair is one of the only international airlines to post high growth and stellar returns through a full cycle, owing mostly to the company's obsessive focus around efficiency and agility. Ryanair has created a deep cost advantage that allows it to price fares at levels that would be unprofitable for the vast majority of peers, leading to continued market share gains. The current industry setup is favorable, as the European in-service short-haul fleet is in short supply. Elevated storage rates are unlikely to revert due to aircraft age and restoration costs. Additionally, there are supply chain challenges and large backlogs that are limiting the pace of delivery of new planes. Ryanair's mid-single-digit capacity growth is locked in through 2034. Recently, its fares have been a bit softer than expected due to a weak consumer in Europe, and capacity hasn't expanded as quickly as expected due to Boeing delivery delays. We view both issues as transitory in nature. Valuation is well below historical averages and is likely to recover over a 3-5 year time horizon.

BSD Analysis:
FMI presents a compelling bull case for Ryanair based on its dominant 20% market share in European aviation and unique low-cost model featuring point-to-point flights, direct booking, secondary airports, and single-variant fleet operations. The manager emphasizes Ryanair's exceptional track record of delivering high growth and returns through full cycles due to obsessive efficiency focus. The investment thesis centers on Ryanair's deep cost advantage enabling fare pricing that would be unprofitable for competitors, driving continued market share gains. FMI highlights favorable industry dynamics including European short-haul fleet shortages, elevated storage costs, and supply chain constraints limiting new aircraft deliveries. With capacity growth locked through 2034, the manager views recent fare softness and Boeing delivery delays as temporary headwinds. The valuation opportunity appears attractive with shares trading below historical averages, positioning for recovery over a 3-5 year horizon.

Pitch Summary:
Quest Diagnostics is one of the largest independent clinical laboratory testing companies in the U.S. with a 24% market share of independent lab testing, and its scale gives it a cost advantage. The clinical testing industry sees steady volume growth, helped by increasing test volume due to an aging population, higher prevalence of chronic disease, and advancements in medical technology that continue to expand the scope of clinical testing. The broader lab industry is an $85 billion market, accounting for only 2% of total healthcare spending, yet influencing over 70% of medical decisions. Today, nearly 60% of diagnostic tests are performed in a hospital or at a hospital outreach laboratory. Importantly, performing the same diagnostic test at an independent lab can cost anywhere between two and five times less than performing the same test in a hospital lab. Quest's average revenue per requisition is under $50. There is a nationwide focus on increasing preventative healthcare and lowering healthcare costs in general. Independent labs are part of the solution, as there is a huge value to be reaped by pushing more volumes through them. In the past, Quest has seen reimbursement challenges from both government and commercial payors. We believe that reimbursement headwinds have largely abated due to all payors recognizing the large cost-benefit of higher volumes flowing through the independent labs. We expect Quest to generate mid-single-digit topline growth and expand margins, leading to high-single-digit earnings growth. With Quest's dividend and share repurchases, there are prospects for a low-double-digit total annual return, which is attractive given the defensive nature of the business and well-below market valuation.

BSD Analysis:
FMI's bull thesis on Quest Diagnostics centers on the company's scale advantages as a leading independent lab with 24% market share and significant cost benefits versus hospital labs. The manager highlights compelling industry dynamics including steady volume growth from aging demographics, chronic disease prevalence, and expanding medical technology scope. The cost arbitrage opportunity is substantial, with independent labs performing tests at 2-5x lower cost than hospital labs, while Quest's average revenue per requisition remains under $50. FMI believes reimbursement headwinds have abated as payors recognize the cost-benefit of independent labs in the broader healthcare cost reduction effort. The investment case projects mid-single-digit revenue growth, margin expansion, and high-single-digit earnings growth. Combined with dividends and buybacks, the manager expects low-double-digit total returns from a defensive business trading at below-market valuation.

Pitch Summary:
Henry Schein is the largest dental distributor in the world, holding a leading market share position in all of its main geographies, and is also a leader in medical distribution. Henry Schein provides value to both product manufacturers and its customers. Manufacturers benefit from cost effective access to a highly fragmented customer base, as well as sales and marketing support for products. Practitioner customers benefit from timely access to a broad range of products, a reduction in the number of vendors they need to deal with directly, inventory management services, and equipment servicing. Henry Schein also sells practice management software that is used by ~40% of dental practices in the U.S., which is a very sticky business. We expect continued strong long-term growth in spending on dental services, which will be driven by an aging population, along with a focus on preventive care and demand for cosmetic dentistry procedures. Schein's stock has been under pressure in the near term because it is still recovering from a cyber-attack that took place late last year, and the macro backdrop continues to be challenged, which has led to muted elective/discretionary sales across the business. The stock is trading well below the market, which we view as attractive given its above-average business quality.

BSD Analysis:
FMI presents a compelling bull case for Henry Schein based on its dominant market position as the world's largest dental distributor with leading share across key geographies. The manager emphasizes the company's value proposition to both manufacturers and practitioners, highlighting sticky revenue streams from practice management software used by 40% of U.S. dental practices. The investment thesis centers on secular growth drivers including an aging population, increased focus on preventive care, and rising demand for cosmetic dentistry procedures. FMI views the current weakness as temporary, attributing it to cyber-attack recovery and macro headwinds affecting elective procedures. The manager sees attractive valuation opportunity with the stock trading below market multiples despite above-average business quality. This appears to be a classic value play on a quality franchise experiencing temporary headwinds.

Pitch Summary:
Ryanair is Europe's largest airline by passenger volume (~20% market share). It employs a very simple, yet unique business model. It flies only point-to-point, books flights almost solely through its website/app, heavily utilizes secondary airports, flies a single-variant fleet, and has a widespread geographic distribution (40 countries and 96 bases), which helps mitigate the impact of strikes or unfavorable regulations that occur in a single geography. Ryanair is one of the only international airlines to post high growth and stellar returns through a full cycle, owing mostly to the company's obsessive focus around efficiency and agility. Ryanair has created a deep cost advantage that allows it to price fares at levels that would be unprofitable for the vast majority of peers, leading to continued market share gains. The current industry setup is favorable, as the European in-service short-haul fleet is in short supply. Elevated storage rates are unlikely to revert due to aircraft age and restoration costs. Additionally, there are supply chain challenges and large backlogs that are limiting the pace of delivery of new planes. Ryanair's mid-single-digit capacity growth is locked in through 2034. Recently, its fares have been a bit softer than expected due to a weak consumer in Europe, and capacity hasn't expanded as quickly as expected due to Boeing delivery delays. We view both issues as transitory in nature. Valuation is well below historical averages and is likely to recover over a 3-5 year time horizon.

BSD Analysis:
FMI presents a compelling bull case for Ryanair based on its dominant European market position with approximately 20% passenger volume share and a highly differentiated low-cost business model. The manager emphasizes Ryanair's operational efficiency through point-to-point flights, direct booking channels, secondary airport utilization, and single-variant fleet operations across 40 countries and 96 bases. This geographic diversification provides resilience against localized disruptions while the company's obsessive focus on efficiency has created sustainable cost advantages enabling fare pricing that would be unprofitable for competitors. FMI highlights favorable industry dynamics including European short-haul fleet shortages, elevated aircraft storage costs, and supply chain constraints limiting new aircraft deliveries. The manager notes Ryanair's capacity growth is secured through 2034, providing visibility into future expansion. While acknowledging near-term headwinds from weak European consumer demand and Boeing delivery delays, FMI views these as temporary issues. The investment thesis is supported by below-average historical valuation with expected recovery over a 3-5 year timeframe, positioning investors to benefit from Ryanair's market share gains and operational excellence.

Pitch Summary:
Quest Diagnostics is one of the largest independent clinical laboratory testing companies in the U.S. with a 24% market share of independent lab testing, and its scale gives it a cost advantage. The clinical testing industry sees steady volume growth, helped by increasing test volume due to an aging population, higher prevalence of chronic disease, and advancements in medical technology that continue to expand the scope of clinical testing. The broader lab industry is an $85 billion market, accounting for only 2% of total healthcare spending, yet influencing over 70% of medical decisions. Today, nearly 60% of diagnostic tests are performed in a hospital or at a hospital outreach laboratory. Importantly, performing the same diagnostic test at an independent lab can cost anywhere between two and five times less than performing the same test in a hospital lab. Quest's average revenue per requisition is under $50. There is a nationwide focus on increasing preventative healthcare and lowering healthcare costs in general. Independent labs are part of the solution, as there is a huge value to be reaped by pushing more volumes through them. In the past, Quest has seen reimbursement challenges from both government and commercial payors. We believe that reimbursement headwinds have largely abated due to all payors recognizing the large cost-benefit of higher volumes flowing through the independent labs. We expect Quest to generate mid-single-digit topline growth and expand margins, leading to high-single-digit earnings growth. With Quest's dividend and share repurchases, there are prospects for a low-double-digit total annual return, which is attractive given the defensive nature of the business and well-below market valuation.

BSD Analysis:
FMI presents a strong bull case for Quest Diagnostics centered on its market-leading position with 24% share of independent lab testing and significant cost advantages from scale. The manager highlights compelling industry dynamics including steady volume growth driven by an aging population, rising chronic disease prevalence, and expanding medical technology capabilities. A key value proposition is Quest's cost efficiency, with independent lab testing costing 2-5 times less than hospital-based testing, while Quest's average revenue per requisition remains under $50. FMI emphasizes the strategic importance of independent labs in the broader healthcare cost reduction initiative, noting they represent only 2% of healthcare spending yet influence 70% of medical decisions. The manager believes previous reimbursement headwinds have largely subsided as payors recognize the cost-benefit advantages. FMI projects mid-single-digit revenue growth and margin expansion leading to high-single-digit earnings growth, with dividend and share repurchases supporting low-double-digit total returns. The investment appeal is enhanced by Quest's defensive business characteristics and below-market valuation.

Pitch Summary:
Henry Schein is the largest dental distributor in the world, holding a leading market share position in all of its main geographies, and is also a leader in medical distribution. Henry Schein provides value to both product manufacturers and its customers. Manufacturers benefit from cost effective access to a highly fragmented customer base, as well as sales and marketing support for products. Practitioner customers benefit from timely access to a broad range of products, a reduction in the number of vendors they need to deal with directly, inventory management services, and equipment servicing. Henry Schein also sells practice management software that is used by ~40% of dental practices in the U.S., which is a very sticky business. We expect continued strong long-term growth in spending on dental services, which will be driven by an aging population, along with a focus on preventive care and demand for cosmetic dentistry procedures. Schein's stock has been under pressure in the near term because it is still recovering from a cyber-attack that took place late last year, and the macro backdrop continues to be challenged, which has led to muted elective/discretionary sales across the business. The stock is trading well below the market, which we view as attractive given its above-average business quality.

BSD Analysis:
FMI presents a compelling bull case for Henry Schein based on its dominant market position as the world's largest dental distributor with leading market share across key geographies. The manager emphasizes the company's dual value proposition, serving both manufacturers through cost-effective customer access and practitioners through comprehensive distribution services. A key competitive advantage highlighted is Henry Schein's practice management software, used by approximately 40% of U.S. dental practices, creating significant customer stickiness. The investment thesis centers on secular growth drivers including an aging population, increased focus on preventive care, and rising demand for cosmetic dentistry procedures. FMI acknowledges near-term headwinds from a recent cyber-attack and challenging macro conditions affecting elective procedures, but views the current valuation as attractive relative to the company's business quality. The manager appears confident in the long-term growth trajectory of dental services spending, positioning Henry Schein to benefit from these favorable demographic and healthcare trends.

Pitch Summary:
Ryanair is Europe's largest airline by passenger volume (~20% market share). It employs a very simple, yet unique business model. It flies only point-to-point, books flights almost solely through its website/app, heavily utilizes secondary airports, flies a single-variant fleet, and has a widespread geographic distribution (40 countries and 96 bases), which helps mitigate the impact of strikes or unfavorable regulations that occur in a single geography. Ryanair is one of the only international airlines to post high growth and stellar returns through a full cycle, owing mostly to the company's obsessive focus around efficiency and agility. Ryanair has created a deep cost advantage that allows it to price fares at levels that would be unprofitable for the vast majority of peers, leading to continued market share gains. The current industry setup is favorable, as the European in-service short-haul fleet is in short supply. Elevated storage rates are unlikely to revert due to aircraft age and restoration costs. Additionally, there are supply chain challenges and large backlogs that are limiting the pace of delivery of new planes. Ryanair's mid-single-digit capacity growth is locked in through 2034. Recently, its fares have been a bit softer than expected due to a weak consumer in Europe, and capacity hasn't expanded as quickly as expected due to Boeing delivery delays. We view both issues as transitory in nature. Valuation is well below historical averages and is likely to recover over a 3-5 year time horizon.

BSD Analysis:
FMI presents a compelling bull case for Ryanair based on its dominant 20% market share in European aviation and unique low-cost business model. The manager emphasizes Ryanair's operational efficiency through point-to-point flights, direct booking channels, secondary airport utilization, and single-variant fleet operations across 40 countries and 96 bases. This geographic diversification provides resilience against localized disruptions while the company's obsessive focus on efficiency has created sustainable cost advantages enabling unprofitable pricing for competitors. Current industry dynamics are favorable with European short-haul fleet shortages, elevated aircraft storage costs, and supply chain constraints limiting new plane deliveries. Ryanair's capacity growth is secured through 2034, providing visibility into future expansion. Near-term headwinds from weak European consumer demand and Boeing delivery delays are viewed as transitory. The manager sees attractive risk-adjusted returns with valuation below historical averages and recovery potential over a 3-5 year timeframe.

Pitch Summary:
Quest Diagnostics is one of the largest independent clinical laboratory testing companies in the U.S. with a 24% market share of independent lab testing, and its scale gives it a cost advantage. The clinical testing industry sees steady volume growth, helped by increasing test volume due to an aging population, higher prevalence of chronic disease, and advancements in medical technology that continue to expand the scope of clinical testing. The broader lab industry is an $85 billion market, accounting for only 2% of total healthcare spending, yet influencing over 70% of medical decisions. Today, nearly 60% of diagnostic tests are performed in a hospital or at a hospital outreach laboratory. Importantly, performing the same diagnostic test at an independent lab can cost anywhere between two and five times less than performing the same test in a hospital lab. Quest's average revenue per requisition is under $50. There is a nationwide focus on increasing preventative healthcare and lowering healthcare costs in general. Independent labs are part of the solution, as there is a huge value to be reaped by pushing more volumes through them. In the past, Quest has seen reimbursement challenges from both government and commercial payors. We believe that reimbursement headwinds have largely abated due to all payors recognizing the large cost-benefit of higher volumes flowing through the independent labs. We expect Quest to generate mid-single-digit topline growth and expand margins, leading to high-single-digit earnings growth. With Quest's dividend and share repurchases, there are prospects for a low-double-digit total annual return, which is attractive given the defensive nature of the business and well-below market valuation.

BSD Analysis:
FMI's bull thesis for Quest Diagnostics centers on the company's dominant 24% market share in independent lab testing and significant cost advantages from scale. The manager highlights compelling industry dynamics including steady volume growth driven by aging demographics, chronic disease prevalence, and expanding medical technology capabilities. A key value proposition is Quest's cost efficiency, with independent lab testing costing 2-5 times less than hospital-based testing while Quest's average revenue per requisition remains under $50. The investment case is strengthened by healthcare cost containment trends favoring independent labs, which represent only 2% of total healthcare spending yet influence over 70% of medical decisions. Previous reimbursement headwinds have largely abated as payors recognize the cost-benefit of independent lab utilization. FMI projects mid-single-digit revenue growth with margin expansion driving high-single-digit earnings growth, combined with dividends and share repurchases targeting low-double-digit total returns at below-market valuations.

Pitch Summary:
Henry Schein is the largest dental distributor in the world, holding a leading market share position in all of its main geographies, and is also a leader in medical distribution. Henry Schein provides value to both product manufacturers and its customers. Manufacturers benefit from cost effective access to a highly fragmented customer base, as well as sales and marketing support for products. Practitioner customers benefit from timely access to a broad range of products, a reduction in the number of vendors they need to deal with directly, inventory management services, and equipment servicing. Henry Schein also sells practice management software that is used by ~40% of dental practices in the U.S., which is a very sticky business. We expect continued strong long-term growth in spending on dental services, which will be driven by an aging population, along with a focus on preventive care and demand for cosmetic dentistry procedures. Schein's stock has been under pressure in the near term because it is still recovering from a cyber-attack that took place late last year, and the macro backdrop continues to be challenged, which has led to muted elective/discretionary sales across the business. The stock is trading well below the market, which we view as attractive given its above-average business quality.

BSD Analysis:
FMI presents a compelling bull case for Henry Schein based on its dominant market position as the world's largest dental distributor with leading share across key geographies. The manager emphasizes the company's value proposition to both manufacturers and practitioners, highlighting cost-effective customer access and comprehensive service offerings including inventory management and equipment servicing. A key competitive moat is their practice management software used by approximately 40% of U.S. dental practices, creating significant customer stickiness. The investment thesis centers on secular growth drivers including an aging population, increased focus on preventive care, and rising demand for cosmetic dentistry procedures. Near-term headwinds from a cyber-attack and challenging macro environment have created an attractive entry point, with the stock trading below market multiples despite above-average business quality. The manager views current weakness as temporary, positioning for recovery as these transitory issues resolve.